Journal article
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers
Abstract
Importance: Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy is associated with an increased risk of breast cancer has not been evaluated in a prospective study.
Objective: To determine the association between HRT use and BRCA1-associated breast cancer.
Authors
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A
Journal
JAMA Oncology, Vol. 4, No. 8, pp. 1059–1065
Publisher
American Medical Association (AMA)
Publication Date
August 1, 2018
DOI
10.1001/jamaoncol.2018.0211
ISSN
2374-2437